Skip to content

The ROS1ders

Bridging ROS1+ Cancer Patients To Research

Menu
  • ABOUT ROS1
    • Drugs to Treat ROS1+ Cancer
    • Clinical Trials for ROS1+ Patients
    • ROS1 Experts
  • BLOG
  • PROJECTS
    • The ROS1 Cancer Model Project
  • RESOURCES
  • ABOUT US
  • CONTACT US
  • DONATE

Crizotinib may be effective again after chemo

Posted on August 27, 2018August 27, 2018Author grayconnectionsCategories News, UncategorizedTags crizotinib, G2032R, ROS1

Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC.

This case is a proof of concept that re-challenging with crizotinib after intervening chemotherapy is feasible in ROS1-rearranged NSCLC with acquired resistance.

Read full article here.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to print (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

Post navigation

Previous Previous post: TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study
Next Next post: Detection of ROS1 rearrangement in lung cancer remains “complex”

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,408 other subscribers

Tags

advocacy ASCO18 brain metastasis cancer models clinical trial Clinical trials community crizotinib diagnosis education Entrectinib G2032R IASLC Webinar Lung cancer Lung Cancer Canada Lungenkrebs mechanisms of resistance Newsletters NICE patient-driven research regulatory approval research results ROS1 ROS1 Cancer ROS1 testing RXDX-101 Side effects support survey survivorship testing guidelines The ROS1ders TPX-0005 UK Xalkori

ROS1 Cancer Research Forum on Facebook

ROS1 Cancer Research Forum on Facebook

ROS1 Social Media

  • View ROS1 Cancer Research Forum’s profile on Facebook
  • View @ros1cancer’s profile on Twitter

Blog Stats

  • 116,514 hits
Powered by WordPress.com.
  • ROS1 Cancer Facebook Group
  • @ros1 on twitter
  • ROS1 on LinkedIn
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: